Italia markets close in 1 hour 15 minutes
FTSE MIB
33.282,14 +374,09 (+1,14%) Dow Jones
38.786,50 +8,40 (+0,02%) Nasdaq
17.877,51 +20,49 (+0,11%) Nikkei 225
38.482,11 +379,67 (+1,00%) Petrolio
80,99 +0,66 (+0,82%) Bitcoin EUR
60.104,98 -680,37 (-1,12%)
NBIX Nov 2024 135.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 12:43PM EDT. Mercato aperto.
| Chiusura precedente | 18,50 |
| Aperto | 18,50 |
| Denaro | 14,10 |
| Domanda | 18,50 |
| Prezzo d'esercizio | 135,00 |
| Scadenza | 2024-11-15 |
| Min-Max giorno | 18,50 - 18,50 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 4 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.